Celegene’s Revlimid Increases Risk Of Additional Cancers, FDA Says

The Food and Drug Administration May 7 said it is informing the public of an increased risk of second primary malignancies in patients with newly diagnosed multiple myeloma who received Revlimid (lenalidomide).

Revlimid, which is manufactured by Summit, N.J.-based Celgene Corp., is used to treat multiple myeloma and a blood disorder known as myelodysplastic syndrome.

Clinical trials conducted after Revlimid was approved showed that newly diagnosed patients treated with Revlimid had an increased risk of developing second primary malignancies compared to similar patients who received a placebo, FDA said. Specifically, these trials showed there was an increased risk of developing ...